Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 461

1.

Mate wareware: Understanding 'dementia' from a Māori perspective.

Dudley M, Menzies O, Elder H, Nathan L, Garrett N, Wilson D.

N Z Med J. 2019 Oct 4;132(1503):66-74.

PMID:
31581183
2.

Peripheral neuropathy in HIV patients on antiretroviral therapy: Does it impact function?

Dudley MT, Borkum M, Basera W, Wearne N, Heckmann JM.

J Neurol Sci. 2019 Sep 6;406:116451. doi: 10.1016/j.jns.2019.116451. [Epub ahead of print]

PMID:
31521960
3.

MomsTalkShots: An individually tailored educational application for maternal and infant vaccines.

Salmon DA, Limaye RJ, Dudley MZ, Oloko OK, Church-Balin C, Ellingson MK, Spina CI, Brewer SE, Orenstein WA, Halsey NA, Chamberlain AT, Bednarczyk RA, Malik FA, Frew PM, O'Leary ST, Omer SB.

Vaccine. 2019 Oct 8;37(43):6478-6485. doi: 10.1016/j.vaccine.2019.08.080. Epub 2019 Sep 7.

PMID:
31506192
4.

The Limits of Power: Wind Energy, Orkney, and the Post-war British State.

Dudley M.

20 Century Br Hist. 2019 Aug 3. pii: hwz024. doi: 10.1093/tcbh/hwz024. [Epub ahead of print]

PMID:
31377787
5.

Randomized controlled trial of the Child Protection Unit: Grade and gender as moderators of CSA prevention concepts in elementary students.

Nickerson AB, Tulledge J, Manges M, Kesselring S, Parks T, Livingston JA, Dudley M.

Child Abuse Negl. 2019 Oct;96:104101. doi: 10.1016/j.chiabu.2019.104101. Epub 2019 Aug 1.

PMID:
31377534
6.

Teacher Outcomes from the Second Step Child Protection Unit: Moderating Roles of Prior Preparedness, and Treatment Acceptability.

Kim S, Nickerson A, Livingston JA, Dudley M, Manges M, Tulledge J, Allen K.

J Child Sex Abus. 2019 Aug-Sep;28(6):726-744. doi: 10.1080/10538712.2019.1620397. Epub 2019 Jun 18.

PMID:
31211660
7.

Development and acceptability of a video-based vaccine promotion tutorial for obstetric care providers.

Chamberlain AT, Limaye RJ, O'Leary ST, Frew PM, Brewer SE, Spina CI, Ellingson MK, Dudley MZ, Orenstein WA, Donnelly MA, Riley LE, Ault KA, Salmon DA, Omer SB.

Vaccine. 2019 May 1;37(19):2532-2536. doi: 10.1016/j.vaccine.2019.03.005. Epub 2019 Apr 5.

PMID:
30962093
8.

Factors Associated with Māori Performance on the WAIS-IV.

Dudley MD, Barker-Collo SL, Wilson DL, Garrett NK.

Arch Clin Neuropsychol. 2019 Feb 26. pii: acy110. doi: 10.1093/arclin/acy110. [Epub ahead of print]

PMID:
30805644
9.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.

Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.

PMID:
30686551
10.

Enhancing uptake of influenza maternal vaccine.

Ellingson MK, Dudley MZ, Limaye RJ, Salmon DA, O'Leary ST, Omer SB.

Expert Rev Vaccines. 2019 Feb;18(2):191-204. doi: 10.1080/14760584.2019.1562907. Epub 2019 Jan 28. Review.

PMID:
30587042
11.

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.

Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01659-18. doi: 10.1128/AAC.01659-18. Print 2019 Jan.

12.

Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Rat Pneumonia Model.

Tarazi Z, Sabet M, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01671-18. doi: 10.1128/AAC.01671-18. Print 2019 Feb.

13.

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS.

Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.

14.

The adolescent grief inventory: Development of a novel grief measurement.

Andriessen K, Hadzi-Pavlovic D, Draper B, Dudley M, Mitchell PB.

J Affect Disord. 2018 Nov;240:203-211. doi: 10.1016/j.jad.2018.07.012. Epub 2018 Aug 3.

PMID:
30077916
15.

Confluence of suicide and drug overdose epidemics in young Australian males: common causality?

Taylor R, Page A, Wodak A, Dudley M, Munot S, Morrell S.

BMC Public Health. 2018 Aug 3;18(1):965. doi: 10.1186/s12889-018-5875-x.

16.

A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.

Redell M, Moeck G, Lucasti C, Durso S, Kennedy C, Fusaro K, Loutit J, Dudley M.

Open Forum Infect Dis. 2018 Mar 19;5(6):ofy051. doi: 10.1093/ofid/ofy051. eCollection 2018 Jun.

17.

Absence of TetB identifies minocycline-susceptible isolates of Acinetobacter baumannii.

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson KJ, Thamlikitkul V, Dudley MN, Redell MA.

Int J Antimicrob Agents. 2018 Sep;52(3):404-406. doi: 10.1016/j.ijantimicag.2018.04.006. Epub 2018 Apr 14.

PMID:
29665446
18.

Harmful or Helpful? A Systematic Review of How Those Bereaved Through Suicide Experience Research Participation.

Andriessen K, Krysinska K, Draper B, Dudley M, Mitchell PB.

Crisis. 2018 Sep;39(5):364-376. doi: 10.1027/0227-5910/a000515. Epub 2018 Apr 5.

PMID:
29618271
19.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.

Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ.

Br J Cancer. 2018 Apr;118(7):938-946. doi: 10.1038/s41416-018-0003-3. Epub 2018 Mar 12.

20.

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.

Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ.

JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438.

21.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02228-17. doi: 10.1128/AAC.02228-17. Print 2018 Apr.

22.

Help-seeking experiences of bereaved adolescents: A qualitative study.

Andriessen K, Lobb E, Mowll J, Dudley M, Draper B, Mitchell PB.

Death Stud. 2019;43(1):1-8. doi: 10.1080/07481187.2018.1426657. Epub 2018 Mar 14.

PMID:
29393826
23.

"Don't bother about me." The grief and mental health of bereaved adolescents.

Andriessen K, Mowll J, Lobb E, Draper B, Dudley M, Mitchell PB.

Death Stud. 2018 Nov-Dec;42(10):607-615. doi: 10.1080/07481187.2017.1415393. Epub 2018 Mar 1.

PMID:
29364783
24.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.

Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W; SOLO I and SOLO II investigators.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01919-17. doi: 10.1128/AAC.01919-17. Print 2018 Apr.

25.

Clinician perspectives on strategies to improve patient maternal immunization acceptability in obstetrics and gynecology practice settings.

Frew PM, Randall LA, Malik F, Limaye RJ, Wilson A, O'Leary ST, Salmon D, Donnelly M, Ault K, Dudley MZ, Fenimore VL, Omer SB.

Hum Vaccin Immunother. 2018 Jul 3;14(7):1548-1557. doi: 10.1080/21645515.2018.1425116. Epub 2018 Feb 15.

26.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.

Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.

27.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.

Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02103-17. doi: 10.1128/AAC.02103-17. Print 2018 Mar.

28.

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.

Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, McConnell T, Kodrasi O, Quigley MF, Heath J, Fan R, Mackay S, Dudley ME, Kassim SH, Zhou J.

J Immunother Cancer. 2017 Nov 21;5(1):85. doi: 10.1186/s40425-017-0293-7.

29.

Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.

Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01969-17. doi: 10.1128/AAC.01969-17. Print 2018 Feb.

30.

Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection.

Trang M, Dudley MN, Bhavnani SM.

Curr Opin Pharmacol. 2017 Oct;36:107-113. doi: 10.1016/j.coph.2017.09.009. Epub 2017 Nov 10. Review.

PMID:
29128853
31.

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.

Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01446-17. doi: 10.1128/AAC.01446-17. Print 2018 Jan.

32.

β-Lactamase inhibitors: what you really need to know.

Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B.

Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Review.

PMID:
29096172
33.

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01904-17. doi: 10.1128/AAC.01904-17. Print 2018 Jan.

34.

A pilot randomized controlled trial of on-line interventions to improve sleep quality in adults after mild or moderate traumatic brain injury.

Theadom A, Barker-Collo S, Jones K, Dudley M, Vincent N, Feigin V.

Clin Rehabil. 2018 May;32(5):619-629. doi: 10.1177/0269215517736671. Epub 2017 Oct 26.

PMID:
29072086
35.

Potency of Meropenem-Vaborbactam in Lung Surfactant.

Rubio-Aparicio D, Loutit J, Dudley M, Lomovskaya O.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01702-17. doi: 10.1128/AAC.01702-17. Print 2018 Jan.

36.

A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure.

Lodise TP, Fan W, Griffith DC, Dudley MN, Sulham KA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01165-17. doi: 10.1128/AAC.01165-17. Print 2018 Jan.

37.

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.

Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01694-17. doi: 10.1128/AAC.01694-17. Print 2017 Dec.

38.

Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.

Rex JH, Talbot GH, Goldberger MJ, Eisenstein BI, Echols RM, Tomayko JF, Dudley MN, Dane A.

Clin Infect Dis. 2017 Jul 1;65(1):141-146. doi: 10.1093/cid/cix246. Review.

39.

Wellness and Thriving in a Student Registered Nurse Anesthetist Population.

Griffin A, Yancey V, Dudley M.

AANA J. 2017 Oct;85(5):325-330.

PMID:
31566531
40.

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov.

41.

Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials.

Alexander EL, Loutit J, Tumbarello M, Wunderink R, Felton T, Daikos G, Fusaro K, White D, Zhang S, Dudley MN.

Open Forum Infect Dis. 2017 Jun 1;4(2):ofx063. doi: 10.1093/ofid/ofx063. eCollection 2017 Spring.

42.

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.

Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, DeLuca A, Mittapalli RK, Munasinghe W, He L, Zalcberg JR, Ngan SY, Komarnitsky P, Michael M.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):418-426. doi: 10.1016/S2468-1253(17)30012-2. Epub 2017 Mar 27.

PMID:
28497757
43.

In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae.

Huang D, Yu B, Diep JK, Sharma R, Dudley M, Monteiro J, Kaye KS, Pogue JM, Abboud CS, Rao GG.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00073-17. doi: 10.1128/AAC.00073-17. Print 2017 Jul.

44.

Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer.

Yoo B, Kavishwar A, Wang P, Ross A, Pantazopoulos P, Dudley M, Moore A, Medarova Z.

Sci Rep. 2017 Mar 21;7:45060. doi: 10.1038/srep45060.

45.

Prevalence of exposure to suicide: A meta-analysis of population-based studies.

Andriessen K, Rahman B, Draper B, Dudley M, Mitchell PB.

J Psychiatr Res. 2017 May;88:113-120. doi: 10.1016/j.jpsychires.2017.01.017. Epub 2017 Feb 3.

PMID:
28199930
46.

A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.

Deniger DC, Kwong ML, Pasetto A, Dudley ME, Wunderlich JR, Langhan MM, Lee CR, Rosenberg SA.

Clin Cancer Res. 2017 Jan 15;23(2):351-362. doi: 10.1158/1078-0432.CCR-16-0906. Epub 2016 Oct 7.

47.

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.

Belley A, Robson R, Francis JL, Adcock DM, Tiefenbacher S, Rubino CM, Moeck G, Sylvester D, Dudley MN, Loutit J.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01968-16. doi: 10.1128/AAC.01968-16. Print 2017 Feb.

48.

Detecting Mutations in the Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus Coinfection.

Dudley MZ, Sheen P, Gilman RH, Ticona E, Friedland JS, Kirwan DE, Caviedes L, Rodriguez R, Cabrera LZ, Coronel J, Grandjean L, Moore DAJ, Evans CA, Huaroto L, Chávez-Pérez V, Zimic M.

Am J Trop Med Hyg. 2016 Dec 7;95(6):1239-1246. doi: 10.4269/ajtmh.15-0711. Epub 2016 Oct 24.

49.

Recognizing staphylococcal scalded skin syndrome.

Dudley M, Parsh B.

Nursing. 2016 Dec;46(12):68. No abstract available.

PMID:
27875404
50.

Development of a potential screening measure for adolescent depression.

Taouk M, Meiser B, Hadzi-Pavlovic D, Dudley M, Mitchell PB.

Aust N Z J Psychiatry. 2017 Jun;51(6):624-633. doi: 10.1177/0004867416672726. Epub 2016 Oct 12.

PMID:
27738233

Supplemental Content

Loading ...
Support Center